Fig. 1: Trial profile. | Nature Communications

Fig. 1: Trial profile.

From: Efficacy and safety of low-dose interleukin 2 for Behçet’s syndrome: a randomized, placebo-controlled, double-blind, phase 2 clinical trial

Fig. 1: Trial profile.

In a 1:1 ratio, 60 eligible patients were assigned to either the low-dose interleukin-2 (LD-IL-2) group or the placebo group by chance. The placebo-controlled treatment lasted for 12 weeks; 26 out of the LD-IL-2 group and 30 out of the placebo group completed the study. During the 12-week follow-up phase, three patients from the LD-IL-2 group and two from the placebo group withdrew from the trial.

Back to article page